-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $184

Benzinga·10/12/2026 21:05:05
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $160 to $184.